UPDATE 1-Vertex issues revenue outlook for cystic fibrosis treatments

Jan 8 (Reuters) - Vertex Pharmaceuticals Inc said on Sunday that it expected full-year 2017 revenue from its Orkambi cystic fibrosis treatment of $1.1 billion to $1.3 billion and revenue from its Kalydeco treatment of $690 million to $710 million.